BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9842975)

  • 1. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.
    Weller M; Rieger J; Grimmel C; Van Meir EG; De Tribolet N; Krajewski S; Reed JC; von Deimling A; Dichgans J
    Int J Cancer; 1998 Dec; 79(6):640-4. PubMed ID: 9842975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
    Trepel M; Groscurth P; Malipiero U; Gulbins E; Dichgans J; Weller M
    J Neurooncol; 1998 Aug; 39(1):19-32. PubMed ID: 9760067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.
    Weller M; Winter S; Schmidt C; Esser P; Fontana A; Dichgans J; Groscurth P
    Int J Cancer; 1997 Nov; 73(5):707-14. PubMed ID: 9398050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2.
    Reber U; Wüllner U; Trepel M; Baumgart J; Seyfried J; Klockgether T; Dichgans J; Weller M
    Biochem Pharmacol; 1998 Feb; 55(3):349-59. PubMed ID: 9484802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas.
    Iwadate Y; Fujimoto S; Tagawa M; Namba H; Sueyoshi K; Hirose M; Sakiyama S
    Int J Cancer; 1996 Jun; 69(3):236-40. PubMed ID: 8682593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy.
    Wang H; Zhang SY; Wang S; Lu J; Wu W; Weng L; Chen D; Zhang Y; Lu Z; Yang J; Chen Y; Zhang X; Chen X; Xi C; Lu D; Zhao S
    Neuro Oncol; 2009 Dec; 11(6):790-802. PubMed ID: 19289490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
    Bartussek C; Naumann U; Weller M
    Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity.
    Glaser T; Winter S; Groscurth P; Safayhi H; Sailer ER; Ammon HP; Schabet M; Weller M
    Br J Cancer; 1999 May; 80(5-6):756-65. PubMed ID: 10360653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics.
    Roth W; Fontana A; Trepel M; Reed JC; Dichgans J; Weller M
    Cancer Immunol Immunother; 1997 Mar; 44(1):55-63. PubMed ID: 9111585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
    Feng R; Dong L
    Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status.
    Borbé R; Rieger J; Weller M
    Cancer Chemother Pharmacol; 1999; 44(3):217-27. PubMed ID: 10453723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
    Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
    Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone?
    Weller M; Schmidt C; Roth W; Dichgans J
    Neurology; 1997 Jun; 48(6):1704-9. PubMed ID: 9191791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gli1 is a potential target for alleviating multidrug resistance of gliomas.
    Cui D; Xu Q; Wang K; Che X
    J Neurol Sci; 2010 Jan; 288(1-2):156-66. PubMed ID: 19818966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
    Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
    J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells.
    Schmidt F; Groscurth P; Kermer M; Dichgans J; Weller M
    Acta Neuropathol; 2001 Mar; 101(3):217-24. PubMed ID: 11307620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of bax in human glioma cell lines.
    Vogelbaum MA; Tong JX; Perugu R; Gutmann DH; Rich KM
    J Neurosurg; 1999 Sep; 91(3):483-9. PubMed ID: 10470825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined radiation and p53 gene therapy of malignant glioma cells.
    Badie B; Goh CS; Klaver J; Herweijer H; Boothman DA
    Cancer Gene Ther; 1999; 6(2):155-62. PubMed ID: 10195882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots.
    Skała E; Sitarek P; Toma M; Szemraj J; Radek M; Nieborowska-Skorska M; Skorski T; Wysokińska H; Śliwiński T
    J Pharm Pharmacol; 2016 Nov; 68(11):1454-1464. PubMed ID: 27696406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis in gliomas: molecular mechanisms and therapeutic implications.
    Steinbach JP; Weller M
    J Neurooncol; 2004 Nov; 70(2):245-54. PubMed ID: 15674481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.